Immunotherapy boosts standard treatment for head and neck cancer in early trial
NCT ID NCT02586207
First seen Jun 27, 2026 · Last updated Jun 27, 2026
Summary
This early-phase trial tested whether adding the immunotherapy drug pembrolizumab to standard chemoradiation is safe and effective for people with advanced head and neck cancer. 59 participants received pembrolizumab before, during, and after their regular treatment. The goal was to see if this combination could improve tumor shrinkage and control the disease, while monitoring side effects.
This is an AI summary of the original study and may miss details. Read our disclaimer.
Get updates
Get notified about this study
Sign up to get updates when this study changes or when new studies for HEAD AND NECK CANCER are added.
By submitting, you agree to our Terms of use
Conditions
The condition(s) this trial relates to.
As listed by the trial registrant
The condition terms exactly as the trial's registrant entered them.
Contacts and locations
Locations
-
Sanford Health Cancer Center
Sioux Falls, South Dakota, 57104, United States
-
Sanford-Bismarck Medical Center
Bismarck, North Dakota, 58501, United States
-
Sanford-Roger Maris Cancer Center
Fargo, North Dakota, 58122, United States
-
UCSD Moores Cancer Center
La Jolla, California, 92093-0698, United States
More trials for these conditions
Other studies related to the condition(s) this trial covers.
- Can tailored nutrition boost recovery from head and neck surgery?
- Can less radiation be safer for throat cancer?
- Can Pre-Surgery immunotherapy prime the immune system to fight head and neck cancer?
- Can a new drug boost the power of chemoradiation against head and neck cancer?
- Exercise after cancer therapy: a new way to gauge prognosis?
- Could a PET scan spare throat cancer patients from High-Dose radiation?